Roivant Sciences Ltd.
$26.08B- Market cap
- $29.96B
- Debt
- +$412.94M
- Cash
- −$4.29B
Capital structure 99% equity / 1% debt · EV / Revenue 3157.76x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ROIV stock price at premium vs KTOS $41.48 current versus $0.08 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at KTOS's multiple
Implied fair value · at ROIV's multiple
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 3157.76x
Capital structure 97% equity / 3% debt · EV / Revenue 6.50x · EV / EBITDA 175.49x
ROIV carries the larger enterprise value at $26.08B against $8.76B; KTOS trades on the lower EV / Revenue multiple (6.50x vs 3157.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
KRATOS DEFENSE & SECURITY SOLUTIONS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.09x
0.13x
Net debt / EBITDA
Leverage against operating earnings
24.52x
-5.83x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$560.60M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
NORTHROP GRUMMAN CORP /DE/
ROIV vs NOC
LOCKHEED MARTIN CORP
ROIV vs LMT
RTX Corp
ROIV vs RTX
BOEING CO
ROIV vs BA
MERCURY SYSTEMS INC
ROIV vs MRCY
$412.94M
$269.50M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.